Should I Buy LBRX? LBRX 2026 Analysis

Should You Buy LB Pharmaceuticals Inc (LBRX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

30.000

1 Day change

-0.17%

52 Week Range

33.470

Analysis Updated At

2026/06/19

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

LB Pharmaceuticals Inc (LBRX) is not a strong buy for a beginner, long-term investor at this time. While the stock has positive analyst ratings and a promising drug pipeline, the lack of recent trading momentum, neutral insider and hedge fund activity, and absence of significant catalysts suggest it is better to hold off on investing until more favorable conditions emerge.

Technical Analysis

The technical indicators show a bullish trend with MACD positively expanding, RSI in the neutral zone at 66.371, and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level (R1: 30.819) but lacks strong momentum.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Analysts maintain a strong buy rating with price targets ranging from $36 to $45, driven by confidence in LB-102's potential across multiple indications. The company's drug pipeline shows promise in treating schizophrenia, bipolar disorder, and major depressive disorder.

Neutral/Negative Catalysts

No recent news or significant trading trends from insiders or hedge funds. Congress trading data is unavailable. Stock trend analysis predicts a potential decline of -1.6% in the next week and -6.35% in the next month, indicating short-term bearish sentiment.

Financial Performance

No financial data available for analysis. The latest quarter's financial snapshot could not be retrieved.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are bullish on LBRX with multiple buy ratings and price targets as high as $45. They highlight the company's innovative approach to neuropsychiatric treatments and the robust efficacy of its lead candidate, LB-102.

3 Analyst Rating

Wall Street analysts forecast LBRX stock price to rise

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 30.050

Low

Averages

High

Current: 30.050

Low

Averages

High

Clear Street

Buy

maintain

$45

AI Analysis

2026-06-15

New

Reason

Clear Street

Price Target

$45

AI Analysis

2026-06-15

New

maintain

Buy

Reason

Clear Street keeps a Buy rating and a $45 price target on LB Pharmaceuticals (LBRX). The firm contends that Neumora Therapeutics (NMRA) Phase 3 KOASTAL failure has no meaningful readthrough to LB-102. LB-102, a dopamine D2/D3 and serotonin 5-HT7 receptor antagonist, is built on the well-established pharmacology of amisulpride, supported by both clinical trial and real-world evidence in depression, and has already delivered robust, consistent P2 efficacy in schizophrenia, the analyst tells investors in a research note. Clear Street further contends that the LB-102 investment thesis remains intact across schizophrenia, bipolar disorder, and MDD, with the Neumora outcome serving more as a validation of mechanism selection than a concern for LB Pharmaceuticals' multi-indication opportunity.

Clear Street

Kaveri Pohlman

Buy

maintain

$45

2026-06-15

New

Reason

Clear Street

Kaveri Pohlman

Price Target

$45

2026-06-15

New

maintain

Buy

Reason

Clear Street analyst Kaveri Pohlman keeps a Buy rating and a $45 price target on LB Pharmaceuticals (LBRX). The firm contends that Neumora Therapeutics (NMRA) Phase 3 KOASTAL failure has no meaningful readthrough to LB-102. LB-102, a dopamine D2/D3 and serotonin 5-HT7 receptor antagonist, is built on the well-established pharmacology of amisulpride, supported by both clinical trial and real-world evidence in depression, and has already delivered robust, consistent P2 efficacy in schizophrenia, the analyst tells investors in a research note. Clear Street further contends that the LB-102 investment thesis remains intact across schizophrenia, bipolar disorder, and MDD, with the Neumora outcome serving more as a validation of mechanism selection than a concern for LB Pharmaceuticals' multi-indication opportunity.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LBRX

Unlock Now

LBRX Should I Buy

LBRX Should I Buy

Should You Buy LB Pharmaceuticals Inc (LBRX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch